ResMed Inc. (RMD) Stock

About ResMed Inc.

ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.

ResMed Inc. is led by CEO Michael J. Farrell, employs 9,980 people, headquartered in San Diego, US, publicly traded since 1995.

ResMed Inc. (RMD) stock trades at $214.29 with a market capitalization of $31.08B. The stock is valued at a price-to-earnings (P/E) ratio of 21.74, price-to-book of 5.03, price-to-sales of 5.29. Over the past 52 weeks the stock has ranged between $180.27 and $293.81, and currently trades 27.1% below its 52-week high. It pays a dividend yielding 1.19%.

On profitability, ResMed Inc. generates a return on equity (ROE) of 23.48% — well above the market average, a sign of a high-quality business, return on capital employed of 28.24%, an operating margin of 32.74%, a net profit margin of 27.44%.

In its most recent fiscal year, ResMed Inc. reported annual revenue of $5.1B, net profit of $1.4B, revenue has compounded at 11.7% a year over the last five years, profit at 17.6% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 0.13 — a conservative balance sheet with little leverage risk, a current ratio of 3.44, total assets of $8.2B, $1.2B in cash and equivalents.

RMD has an average daily trading volume of 1,530,000 shares, a beta of 0.78 (less volatile than the overall market).

Official website: www.resmed.com